Anvesana
生物技术研究
New York，NY 301 位关注者
Anvesana is leveraging our RNAseq analysis platform to treat diseases caused by insufficient protein production.
关于我们
Anvesana is developing therapeutics that increase the expression of specific proteins in order to treat disease. Insufficient protein production is the root cause of many rare genetic disorders and can exacerbate symptoms in larger more genetically complex diseases. Our core technology consists of an RNA-sequence analysis pipeline developed in the laboratory of Dr. Thomas Tuschl, cofounder of Alnylam Pharmaceuticals. Our platform queries mRNA sequence data to identify targetable regions for up-regulating gene expression using anti-sense oligonucleotides.
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- New York，NY
- 类型
- 私人持股
- 创立
- 2019
地点
-
主要
获取路线
430 E. 29th St. Floor 14
US，NY，New York，10016